Expanded Access Program With Nivolumab to Treat Melanoma

• Status: No longer available
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Nivolumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• ECOG Performance Status of 0-1

• Histologically confirmed malignant melanoma

• Progressed on or after treatment with an anti-CTLA4

Exclusion Criteria:

• Active brain metastases

• Life Expectancy <6 weeks

• Subjects who received prior therapy targeting T-cell costimulation or checkpoint pathways except for Anti CTLA-4 therapy

• Subjects with autoimmune disease